[go: up one dir, main page]

DE60138097D1 - FOR A TUMOR NEKROSIS FACTOR SIMILAR, APOPTOSIS-INDUCTIVE LIGAND RECEPTOR SELECTIVE ANTIBODY AND ITS APPLICATIONS - Google Patents

FOR A TUMOR NEKROSIS FACTOR SIMILAR, APOPTOSIS-INDUCTIVE LIGAND RECEPTOR SELECTIVE ANTIBODY AND ITS APPLICATIONS

Info

Publication number
DE60138097D1
DE60138097D1 DE60138097T DE60138097T DE60138097D1 DE 60138097 D1 DE60138097 D1 DE 60138097D1 DE 60138097 T DE60138097 T DE 60138097T DE 60138097 T DE60138097 T DE 60138097T DE 60138097 D1 DE60138097 D1 DE 60138097D1
Authority
DE
Germany
Prior art keywords
apoptosis
nekrosis
inductive
tumor
applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138097T
Other languages
German (de)
Inventor
Tong Zhou
Kimihisa Ichikawa
Robert P Kimberly
William J Koopman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Application granted granted Critical
Publication of DE60138097D1 publication Critical patent/DE60138097D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

A purified antibody is disclosed which specifically binds a TRAIL receptor DR5, wherein said antibody: a) has apoptosis-inducing activity in the absence of secondary crosslinking in target cells expressing DR5 in vitro, wherein the apoptosis-inducing activity in vitro is characterized by less than 70% target cell viability at an antibody concentration of 2.5 pg/ml; b) has tumoricidal activity against tumor cells expressing DR5 in vivo; and c) does not bind TRAIL receptor DR4, DcR1, or DcR2.
DE60138097T 2000-05-02 2001-05-02 FOR A TUMOR NEKROSIS FACTOR SIMILAR, APOPTOSIS-INDUCTIVE LIGAND RECEPTOR SELECTIVE ANTIBODY AND ITS APPLICATIONS Expired - Lifetime DE60138097D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20134400P 2000-05-02 2000-05-02
PCT/US2001/014151 WO2001083560A1 (en) 2000-05-02 2001-05-02 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Publications (1)

Publication Number Publication Date
DE60138097D1 true DE60138097D1 (en) 2009-05-07

Family

ID=22745456

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138097T Expired - Lifetime DE60138097D1 (en) 2000-05-02 2001-05-02 FOR A TUMOR NEKROSIS FACTOR SIMILAR, APOPTOSIS-INDUCTIVE LIGAND RECEPTOR SELECTIVE ANTIBODY AND ITS APPLICATIONS

Country Status (27)

Country Link
US (6) US7244429B2 (en)
EP (4) EP2065401B1 (en)
JP (4) JP4156238B2 (en)
KR (2) KR100817967B1 (en)
CN (2) CN100497388C (en)
AT (1) ATE426615T1 (en)
AU (2) AU2001259366B2 (en)
BG (3) BG65929B1 (en)
BR (1) BR0110547A (en)
CA (1) CA2407965C (en)
CY (1) CY1109179T1 (en)
CZ (2) CZ304614B6 (en)
DE (1) DE60138097D1 (en)
DK (1) DK1287035T3 (en)
EE (1) EE05548B1 (en)
ES (1) ES2323448T3 (en)
HU (2) HU229417B1 (en)
IL (1) IL152605A0 (en)
MX (1) MXPA02010823A (en)
NO (2) NO329843B1 (en)
NZ (1) NZ522881A (en)
PL (1) PL211733B1 (en)
PT (1) PT1287035E (en)
RU (1) RU2298013C2 (en)
TW (1) TWI318983B (en)
WO (1) WO2001083560A1 (en)
ZA (1) ZA200209230B (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
NZ508381A (en) 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
CA2369371A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
KR100942393B1 (en) 2001-05-25 2010-02-17 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to the TRAI receptor
KR100866117B1 (en) 2001-10-19 2008-10-31 바스큘라 바이오제닉스 리미티드 Polynucleotide Constructs, Pharmaceutical Compositions and Methods for Targeting Inhibitory Modulation of Angiogenesis and Anticancer Treatment
JP4663232B2 (en) * 2001-11-01 2011-04-06 ザ ユーエービー リサーチ ファウンデーション Combination of antibodies selective for tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
ES2357225T3 (en) * 2001-11-01 2011-04-20 Uab Research Foundation COMBINATIONS OF ANTI-DR5 ANTIBODIES AND ANTI-DR4 ANTIBODIES AND OTHER THERAPEUTIC AGENTS.
CN1610696A (en) * 2001-12-20 2005-04-27 人体基因组科学有限公司 Antibodies that immunospecifically bind to TRAIL receptors
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
DE10210427A1 (en) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Human monoclonal antibody
WO2004005351A2 (en) * 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
DE10311248A1 (en) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Human monoclonal antibody
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (en) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Human monoclonal antibody with fatliquoring effect
CN1980957A (en) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 Receptor coupling agents and therapeutic uses thereof
CN100427505C (en) * 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 Anti-human tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 monoclonal antibody (AD5-10) and its preparation method and use
AU2005316193B2 (en) * 2004-12-13 2012-05-17 Cephalon Australia (Vic) Pty Ltd Osteoprotegerin variant proteins
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1846034A4 (en) 2005-02-02 2010-11-10 Uab Research Foundation AGENTS AND METHODS FOR REDUCING AGONIST RESISTANCE OF APOPTOSIS-INDUCING DEATH RECEPTORS
JP5004154B2 (en) * 2005-04-06 2012-08-22 一般財団法人化学及血清療法研究所 Recombinant anti-botulinum neurotoxin antibody
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
UA97096C2 (en) * 2005-08-31 2012-01-10 Емджен Інк. Isolated antibody that specifically binds to trail receptor-2 (tr-2)
PE20071101A1 (en) * 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
KR20090031359A (en) 2006-05-16 2009-03-25 교와 핫꼬 기린 가부시키가이샤 High secretion production method of protein
JP5597793B2 (en) 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション ILT3-binding molecules and uses thereof
KR100847010B1 (en) * 2006-07-05 2008-07-17 아주대학교산학협력단 Antibodies that specifically bind to apoptosis receptor 5 (DR5) and compositions for preventing or treating cancer comprising the same
KR100804126B1 (en) 2007-02-09 2008-02-19 아주대학교산학협력단 Monovalent human monoclonal antibodies and antigen binding fragments thereof that specifically bind to receptors of tumor necrosis factor-associated apoptosis-inducing ligand
AR066913A1 (en) * 2007-06-08 2009-09-23 Irm Llc METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS
CN101820913A (en) * 2007-08-09 2010-09-01 第一三共株式会社 Immunoliposomes inducing apoptosis in cells expressing death domain-containing receptors
EP2210940B2 (en) 2007-10-31 2018-07-18 Daiichi Sankyo Company, Limited Method for high-level secretion and production of protein
WO2010047509A2 (en) * 2008-10-24 2010-04-29 아주대학교 산학협력단 Anti-dr5 antibody with improved affinity and stability, and composition for cancer prevention or treatment including same
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
KR101278690B1 (en) * 2009-10-19 2013-06-24 한올바이오파마주식회사 Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereofand method for preparing the same
US9527915B2 (en) 2009-11-05 2016-12-27 The Uab Research Foundation Treating basal-like genotype cancers
WO2011084623A1 (en) 2009-12-16 2011-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
KR20120140658A (en) 2010-02-12 2012-12-31 파마사이언스 인크. Iap bir domain binding compounds
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
JP5918143B2 (en) * 2010-10-29 2016-05-18 第一三共株式会社 New anti-DR5 antibody
CN110038135B (en) 2011-03-17 2021-03-05 伯明翰大学 redirected immunotherapy
CA2834776A1 (en) * 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
KR20150036274A (en) 2012-07-19 2015-04-07 알레시아 바이오쎄라퓨틱스 인코포레이티드 Anti-siglec-15 antibodies
NZ731881A (en) * 2012-07-25 2022-07-29 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CN103074425B (en) * 2012-12-29 2014-01-01 深圳市第三人民医院 Uses of the CD263 gene
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN104710533A (en) * 2013-12-12 2015-06-17 中国科学院深圳先进技术研究院 sDR5-Fc fusion protein and uses thereof
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
TWI688572B (en) 2015-01-26 2020-03-21 美商宏觀基因股份有限公司 Multivalent molecules comprising dr5-binding domains
CN105061604B (en) * 2015-08-19 2018-03-16 河南大学 SDR5 Fc fusion proteins mutant and its application
EP3368076B1 (en) 2015-10-30 2025-04-30 Galaxy Biotech, LLC Highly potent antibodies binding to death receptor 4 and death receptor 5
US20190202926A1 (en) 2015-12-01 2019-07-04 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
CN106924735A (en) * 2015-12-29 2017-07-07 上海交通大学医学院附属瑞金医院 Use of dopamine type 1 receptor agonist in the preparation of drugs for treating tumors
US10849912B2 (en) 2016-02-09 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
WO2017149538A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
KR101926166B1 (en) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 Method of measuring of nk cell activity using receptor synergy and diagnosing of nk cell activity-mediated desease
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
KR101926834B1 (en) * 2017-03-21 2018-12-07 동아에스티 주식회사 Anti-dr5 antibody and use thereof
CN111328335A (en) 2017-06-07 2020-06-23 根马布私人有限公司 Therapeutic antibodies based on mutant IGG hexamers
KR101951025B1 (en) 2017-08-17 2019-02-21 서울대학교산학협력단 Pharmaceutical composition for preventing or treating diseases caused by overexpression of CX3CL1 chemokine comprising death receptor inhibitor
WO2019060718A1 (en) * 2017-09-22 2019-03-28 Immunogen, Inc. Separation of triple-light chain antibodies using cation exchange chromatography
WO2019100193A1 (en) * 2017-11-21 2019-05-31 深圳先进技术研究院 Anti-dr5 antibody and preparation method therefor and use thereof
WO2019100194A1 (en) * 2017-11-21 2019-05-31 深圳先进技术研究院 Anti-dr5 antibody and preparation method therefor and use thereof
CN108251443A (en) * 2018-01-23 2018-07-06 深圳市人民医院 A kind of TNFRSF10C recombinant plasmids, preparation method and applications
US12018045B2 (en) 2018-03-06 2024-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
CN110305211A (en) 2018-03-20 2019-10-08 鸿运华宁（杭州）生物医药有限公司 GIPR antibody and fusion protein thereof with GLP-1, and pharmaceutical composition and application thereof
US11702482B2 (en) 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
WO2022154664A1 (en) 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
AU6250098A (en) 1997-01-28 1998-08-18 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
NZ508381A (en) * 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
IL123888A0 (en) 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
WO1998046643A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
JP2001511653A (en) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Apo-2 receptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
IL133920A0 (en) * 1997-07-15 2001-04-30 Immunex Corp Trail receptor
EP0934421A1 (en) 1997-08-06 1999-08-11 Laboratorio Medinfar-Produtos Farmaceuticos LDA. DNA INTEGRATION INTO "MYCOBACTERIUM spp." GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM
WO1999009365A1 (en) * 1997-08-13 1999-02-25 Ufe Solar Gmbh Sorption trap arrangement and method for storing heat
AU8784498A (en) * 1997-08-15 1999-03-08 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DE69837606T2 (en) 1997-09-12 2008-02-14 Biogen Idec Ma Inc., Cambridge CYSTEIN RICH RECEPTORS TRAIN
US7105640B2 (en) * 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
US20040120947A1 (en) 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
PT1053256E (en) 1998-01-26 2011-09-28 Genentech Inc Antibodies to death receptor 4 (dr4) and uses thereof
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US6534061B1 (en) * 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
CA2369371A1 (en) 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
EP1178828A4 (en) 1999-05-06 2004-10-13 Human Genome Sciences Inc Death domain containing receptor 4
ES2325305T3 (en) 1999-05-28 2009-09-01 Genentech, Inc. CHEMICAL DR4 ANTIBODIES AND USES OF THE SAME.
ATE330972T1 (en) 1999-06-09 2006-07-15 Genentech Inc APO-2L RECEPTOR AGONIST AND CPT-11 SYNERGY EFFECT
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
CA2384762A1 (en) 1999-09-15 2001-03-22 Genentech, Inc. Apo-2 receptor antibodies
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2426710A1 (en) 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6965023B2 (en) * 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
ES2357225T3 (en) 2001-11-01 2011-04-20 Uab Research Foundation COMBINATIONS OF ANTI-DR5 ANTIBODIES AND ANTI-DR4 ANTIBODIES AND OTHER THERAPEUTIC AGENTS.
JP4663232B2 (en) 2001-11-01 2011-04-06 ザ ユーエービー リサーチ ファウンデーション Combination of antibodies selective for tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents

Also Published As

Publication number Publication date
CZ2006291A3 (en) 2017-11-01
JP3892466B2 (en) 2007-03-14
MXPA02010823A (en) 2004-05-05
RU2002132255A (en) 2005-01-20
HUP0400951A2 (en) 2004-07-28
HU229417B1 (en) 2013-12-30
BR0110547A (en) 2004-06-22
IL152605A0 (en) 2003-06-24
US7244429B2 (en) 2007-07-17
TWI318983B (en) 2010-01-01
ZA200209230B (en) 2004-03-16
NZ522881A (en) 2005-05-27
ATE426615T1 (en) 2009-04-15
CN101585881A (en) 2009-11-25
JP2005232187A (en) 2005-09-02
AU5936601A (en) 2001-11-12
US8067001B2 (en) 2011-11-29
RU2298013C2 (en) 2007-04-27
HUP0400951A3 (en) 2012-09-28
EP2065400B1 (en) 2014-11-05
JP4156238B2 (en) 2008-09-24
NO329843B1 (en) 2011-01-10
US20070298039A1 (en) 2007-12-27
CA2407965A1 (en) 2001-11-08
NO20025253D0 (en) 2002-11-01
EP2368910A1 (en) 2011-09-28
KR100817967B1 (en) 2008-03-31
HK1050372A1 (en) 2003-06-20
AU2001259366B2 (en) 2005-09-08
EP2065400A2 (en) 2009-06-03
EE200200621A (en) 2004-06-15
KR20060092292A (en) 2006-08-22
US8329180B2 (en) 2012-12-11
BG65929B1 (en) 2010-05-31
JP2007091749A (en) 2007-04-12
HK1162524A1 (en) 2012-08-31
US20110008324A1 (en) 2011-01-13
NO338228B1 (en) 2016-08-08
PT1287035E (en) 2009-06-30
KR20030055177A (en) 2003-07-02
EP1287035A4 (en) 2004-09-29
BG109275A (en) 2006-10-31
US20140308288A1 (en) 2014-10-16
CY1109179T1 (en) 2014-07-02
US20130243780A1 (en) 2013-09-19
CZ20023917A3 (en) 2003-05-14
US9700618B2 (en) 2017-07-11
ES2323448T3 (en) 2009-07-16
EP2368910B1 (en) 2016-02-10
CN100497388C (en) 2009-06-10
EE05548B1 (en) 2012-06-15
CN1440424A (en) 2003-09-03
US20120076792A1 (en) 2012-03-29
EP1287035A1 (en) 2003-03-05
EP1287035B1 (en) 2009-03-25
HK1126506A1 (en) 2009-09-04
CN101585881B (en) 2014-11-26
NO20025253L (en) 2002-12-18
US20030190687A1 (en) 2003-10-09
CZ304614B6 (en) 2014-08-06
PL211733B1 (en) 2012-06-29
EP2065401A3 (en) 2009-07-22
JP4575975B2 (en) 2010-11-04
PL366195A1 (en) 2005-01-24
EP2065400A3 (en) 2009-07-22
EP2065401A2 (en) 2009-06-03
HU0500800D0 (en) 2005-10-28
US8715668B2 (en) 2014-05-06
CA2407965C (en) 2014-10-14
BG66153B1 (en) 2011-08-31
EP2065401B1 (en) 2016-08-10
JP2004502409A (en) 2004-01-29
HU230399B1 (en) 2016-04-28
NO20054145L (en) 2002-12-18
DK1287035T3 (en) 2009-06-15
BG107275A (en) 2004-09-30
US7790165B2 (en) 2010-09-07
CZ306996B6 (en) 2017-11-01
JP2009005707A (en) 2009-01-15
WO2001083560A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
DE60138097D1 (en) FOR A TUMOR NEKROSIS FACTOR SIMILAR, APOPTOSIS-INDUCTIVE LIGAND RECEPTOR SELECTIVE ANTIBODY AND ITS APPLICATIONS
EP2338915A3 (en) Anti-VEGF antibodies
EP1325932A3 (en) Anti-vegf antibodies
ATE277058T1 (en) POLYAZOMACROCYCLOFLUOROMONOALKYLPHOSPHENIC ACID, THEIR COMPLEXES FOR USE AS CONTRAST AGENTS
PT1315520E (en) USE OF BIASPECIFIC AND TRIESPECIFIC TRIFUNCTIONAL ANTIBODIES FOR THE TREATMENT OF MALIGNANT ASCITES
WO1997037029B1 (en) MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF
AU2001258567A1 (en) Humanised antibodies to the epidermal growth factor receptor
ATE412432T1 (en) INTERNALIZING ERBB2 ANTIBODIES
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
AU3862097A (en) Catalytic nucleic acid and its medical use
ES2139043T3 (en) AZACICLOHEXAPEPTIDE COMPOUNDS.
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
BR0116686A (en) Silenced anti-cd28 Antibodies and usage
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
BR0308401A (en) Isolated human anti-hfasl antibody, or antigen binding portion thereof, isolated nucleic acid molecule, vector, host cell, methods for inhibiting hfasl, and fasl activities, and for treating or preventing a disorder in which the activity fasl is harmful, pharmaceutical composition, and use of antibody or fragment.
ES2127531T3 (en) MEDICATION FOR PROLONGED IMMUNOSUPPRESSION AND ELIMINATION OF TUMOR CELLS.
IL126442A0 (en) Implantable agarose-collagen beads containing cells which produce a diffusible biological product and uses thereof
BR9904947A (en) Material for use as a sliding surface for a bearing, and a plain bearing having a sliding surface
WO2005014823A3 (en) Targeted carrier fusions for delivery of chemotherapeutic agents
NZ512332A (en) Potassium channel interactors and uses therefor
AU5569600A (en) Novel protein and dna thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition